Jupiter Neurosciences CSO holds 2.99M shares
Jupiter Neurosciences, Inc. director and Chief Scientific Officer Hayward Marshall A. reported multiple equity award exercises that increased his direct common stock holdings.
Rhea-AI Filing Summary
Jupiter Neurosciences, Inc. director and Chief Scientific Officer Hayward Marshall A. reported multiple equity award exercises that increased his direct common stock holdings. On June 2, 2025 he exercised restricted stock awards and restricted stock units for a combined 789,195 shares of common stock. On March 2, 2026 he exercised a stock option for 225,000 shares of common stock at a conversion price of $0.01 per share, ahead of the option’s March 15, 2026 expiration. In total, the transactions reflect exercises of 1,014,195 shares from derivative awards into common stock, resulting in 2,995,077 common shares held directly after the most recent transaction. Footnotes state that the derivative securities convert into common stock on a one-for-one basis and that certain awards vested upon expiration of the IPO lock-up period or under the company’s 2016 Equity Incentive Plan.
Positive
- None.
Negative
- None.
Filing Explained
Completed award and option exercises leave the reporting officer with 2,995,077 directly held common shares; the filing reports no sale.
The July 13 Form 4 reports that Jupiter Neurosciences Chief Scientific Officer and director Marshall A. Hayward completed three code-M transactions—two restricted stock awards dated
The filing changes the reported form of the position from derivative awards to common stock: the derivative holdings are shown as zero after the transactions, while common-stock holdings are shown as 2,370,675, 2,770,077, and 2,995,077 after each reported transaction.
Under the supplied Form 4 definitions, code M identifies an option or derivative exercise; the filing says the securities convert into common stock on a one-for-one basis, and the option's exercise price was
The filing identifies vesting mechanics rather than a sale: the first two awards vested when the issuer's initial-public-offering lock-up expired, and the option shares had vested 100% on
The disclosed structural effect is on the reporting person's holdings, not a reported issuer-level financing or other change for existing common holders, so the filing itself supports a neutral holder-impact rating.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F3 | 225,000 | $0.00 | $0.00 |
| Exercise | Common Stock F3 | 225,000 | -- | -- |
| Exercise | Restricted Stock Units F1, F2 | 389,793 | $0.00 | $0.00 |
| Exercise | Restricted Stock Award F1, F2 | 399,402 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 389,793 | -- | -- |
| Exercise | Common Stock F1 | 399,402 | -- | -- |
Footnotes (3)
- F1. These securities convert into common stock on a one-for-one basis.
- F2. These awards vested on the expiration of the lock-up period for the Issuer's initial public offering.
- F3. The shares underlying this option vested 100% on January 1, 2016 under the Company's 2016 Equity Incentive Plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
